Combination chemotherapy with @entity1259 and XXXX as first-line treatment in @entity0 .

@entity1 @entity137 @entity0 @entity66 @entity1138 @entity1259 @entity74 @entity166
From December 1988 to February 1991, 112 consecutive @entity1 were submitted to @entity1259 + @entity1138 chemotherapy as first-line treatment for @entity0 . @entity1259 (75 mg/m2) was given every 3 weeks and @entity1138 (10 mg/m2) every 6 weeks. Only @entity1 with visceral involvement or with a disease-free interval of less than 12 months were considered eligible. 102 @entity1 were evaluated for response and @entity137 in the present analysis. The main sites of involvement were viscera, soft tissues, bone in 71 (69.6%), 19 (18.6%) and 12 (11.8%) @entity1 , respectively. Multiple site involvement was present in 66 (64.7%) cases. A total of 726 courses of therapy were administered (range 2-14; mean 7.2). Follow-up ranged from 96 to 210 weeks (median follow-up 138 weeks). Response rate was complete response (CR): 21.6% [95% confidence interval (CI) +/- 0.8], partial response (PR) 49.0% (95% CI +/- 0.1), @entity66 ( @entity66 ) 12.7% (95% CI +/- 0.1), @entity74 ( @entity74 ) 16.7% (95% CI +/- 0.1), CR + PR: 70.6% (95% CI +/- 0.1). Median values of survival and time to progression were 79.4 and 42 weeks, respectively. At 2 years, 37.2 +/- 4.7% and 12.8 +/- 3.3% of the @entity1 , respectively, were alive or without evidence of progression. @entity137 was generally mild. One hundred and four (14.3%) cycles in 53 @entity1 were delayed due to haematological (82) or cardiac (3) @entity137 , @entity166 (11) or causes not related to the treatment (8).
